TY - JOUR
T1 - How did we get a COVID-19 vaccine in less than 1 year?
AU - The AACR COVID-19 and Cancer Task Force
AU - Wherry, E. John
AU - Jaffee, Elizabeth M.
AU - Warren, Nicholas
AU - D'Souza, Gypsyamber
AU - Ribas, Antoni
N1 - Funding Information:
E.J. Wherry reported a patent for U.S. Patent number 10,370,446 licensed to Roche/Genentech; and E.J. Wherry is a founder of Surface Oncology and Arsenal Biosciences. E.M. Jaffee reported grants and nonfinancial support from BMS; personal fees from Genocea, Achilles, DragonFly, CSTONE, Parker Institute, and candel; other from AbMeta; grants from Lustgarten outside the submitted work; in addition, E.M. Jaffee had a patent for GVAX issued. N. Warren reported nonfinancial support and other from Dartmouth College outside the submitted work; and is a full-time employee of the AACR. G. D’Souza reported grants from NIH during the conduct of the study. A. Ribas reported personal fees from Amgen, Chugai, Genentech, Merck, Novartis, Roche, Sanofi, Vedanta, 4C Biomed, Apricity, Arcus, Highlight, Compugen, ImaginAb, MapKure, Merus, Rgenix, Lutris, PACT Pharma, Tango, Advaxis, CytomX, Five Prime, RAPT, Isoplexis, and Kite-Gilead; and grants from NCI, Agilent, Bristol-Myers Squibb through Stand Up to Cancer (SU2C), the Melanoma Research Alliance, and the Parker Institute for Cancer Immunotherapy outside the submitted work. No potential conflicts of interest were disclosed by the other authors.
Funding Information:
E.J. Wherry was supported by NIH grants AI105343, AI112521, AI082630, AI201085, AI123539, and AI117950. A. Ribas is supported by NIH grants R35 CA197633, P01 CA244118, and P30 CA016042, Mary Tanner and Maurizio Grimaldi, and The Ressler Family Fund. E.J. Wherry. and A. Ribas are also supported by the Parker Institute for Cancer Immunotherapy.
Publisher Copyright:
© 2021 American Association for Cancer Research.
PY - 2021/4
Y1 - 2021/4
N2 - The successful development of COVID-19 vaccines within an unprecedented short time needs to be followed by rapid vaccine uptake, in particular, in high-risk populations such as patients with cancer. It is important for the scientific research community and cancer physicians to convey the knowledge behind the COVID-19 vaccine development and contribute to build the required trust on their use.
AB - The successful development of COVID-19 vaccines within an unprecedented short time needs to be followed by rapid vaccine uptake, in particular, in high-risk populations such as patients with cancer. It is important for the scientific research community and cancer physicians to convey the knowledge behind the COVID-19 vaccine development and contribute to build the required trust on their use.
UR - http://www.scopus.com/inward/record.url?scp=85104124659&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85104124659&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-21-0079
DO - 10.1158/1078-0432.CCR-21-0079
M3 - Review article
C2 - 33542081
AN - SCOPUS:85104124659
SN - 1078-0432
VL - 27
SP - 2136
EP - 2138
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 8
ER -